Skip Navigation LinksHome > Published Ahead-of-Print > Characteristics and Prognostic Analysis of 69 Patients With...
American Journal of Clinical Oncology:
doi: 10.1097/COC.0000000000000101
Original Article: PDF Only

Characteristics and Prognostic Analysis of 69 Patients With Pulmonary Sarcomatoid Carcinoma.

Lin, Yongbin MD, PhD; Yang, Han MD, PhD; Cai, Qingqing MD, PhD; Wang, Daofeng MD, PhD; Rao, Huilan MD, PhD; Lin, Suxia MD, PhD; Long, Hao MD, PhD; Fu, Jianhua MD, PhD; Zhang, Lanjun MD, PhD; Lin, Peng MD, PhD; Xu, Guangchuan MD; Rong, Tiehua MD; Xiong, Xiaoxing MD, PhD; Ma, Guowei MD, PhD; Liang, Ying MD, PhD

Published Ahead-of-Print
Collapse Box

Abstract

Background: Pulmonary sarcomatoid carcinoma (PSC) is a rare malignancy.

Methods: A total of 69 patients with PSC treated at a single institution in southern China with long-term follow-up were evaluated in this study. We analyzed the clinical characteristics, immunohistochemical profiles, epidermal growth factor receptor mutation status, K-RAS mutation status, treatments, and prognosis.

Results: PSC mainly occurred in young male patients with a history of smoking. Most patients received multimodality treatments and the majority had early-stage disease. The median survival time was 19.1 months, and the 5-year survival rate was 17.4%. The patients without distant metastasis, with normal or higher body mass index (>=18.5), with normal hemoglobin, with smaller tumor size (<=4 cm), and those who received complete resection had significantly better overall survival (P<0.05). The patients with pleomorphic carcinoma had much worse prognosis. In a Cox regression model, M stage, pathology, and having received a complete resection were independent prognostic factors (P<0.05).

Conclusions: PSC is a unique lung malignancy with poor prognosis. Patients receiving complete resection had better prognosis, likely a reflection of early-stage disease. Neither neoadjuvant nor adjuvant chemotherapy improved patient survival for those with early-stage disease. The retrospective design and small sample size limited the generalizability. Future multicenter collaborations may be necessary to determine the optimal treatment.

(C) 2014 by Lippincott Williams & Wilkins, Inc

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/AJCOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.